Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases
AbstractThrombotic disorders represent the major share of the various cardiovascular diseases, and significant progress has been made in the development of synthetic thrombin inhibitors as new anticoagulants. In addition to the development of highly potent and selective inhibitors with improved safety and suitable half-life, several allosteric inhibitors have been designed and synthesized, that did not fully nullify the procoagulant signal and thus could result in reduced bleeding complications. Furthermore, natural products with thrombin inhibitory activity have been isolated, and some natural products have been modified in order to improve their inhibitory activity and metabolic stability. This review summarizes the development of orally active thrombin inhibitors for the treatment of thrombotic disorder diseases, which could serve as a reference for the interested researchers. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
He, L.-W.; Dai, W.-C.; Li, N.-G. Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases. Molecules 2015, 20, 11046-11062.
He L-W, Dai W-C, Li N-G. Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases. Molecules. 2015; 20(6):11046-11062.Chicago/Turabian Style
He, Li-Wei; Dai, Wei-Chen; Li, Nian-Guang. 2015. "Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases." Molecules 20, no. 6: 11046-11062.